Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)
NCT03263650Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Olaparib Maintenance with Observation Only (2 arms). Primary endpoint: Progression-Free Survival at 1 year. Started Oct 2017; status: completed.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03263650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263650.